New combo therapy targets hard-to-treat blood cancers in phase 2 trial
NCT ID NCT07153497
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests whether adding the drug olutasidenib to standard treatments helps people with certain blood cancers (AML or MDS) that have an IDH1 gene mutation. About 132 adults will receive either standard therapy alone or with olutasidenib. The goal is to see if the combination leads to higher remission rates and better blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.